Report of diabetes mellitus remission in a cat by orally administered glibenclamide

Abstract Clinical remission of diabetes mellitus which is one of the most commonly encountered endocrine diseases in cats is not very frequent. A 3-year-old male castrated Russian Blue cat with a history of excessive water intake and urination as well as weight loss, lethargy, and unkempt hair coat was referred to us. Type 2 diabetes mellitus was diagnosed based on clinical signs of laboratory findings in this cat. The cat was completely treated in six weeks by orally administered glibenclamide. Based on previously reported studies many factors are involved in the remission of diabetes. Most of these are due to the possibility of reversal of glucotoxicity with insulin injections or orally administered sulfonylurea drugs associated with a reduction of carbohydrates in the diet. The animal subject was monitored for 1 year after remission. The cat was normal in blood glucose after each follow-up. To the best of the authors’ knowledge, this clinical description is the first report of remission in a cat with type 2 diabetes mellitus by glibenclamide in the veterinary literature reported from Iran.
Source: Comparative Clinical Pathology - Category: Pathology Source Type: research

Related Links:

We report a case of a 36-year-old woman with type 2 diabetes mellitus and a one-year of primary infertility. Following oral ovulation induction cycles and IUI, diagnosis of heterotopic cervical pregnancy was made by ultrasonography at 7.4 weeks of gestation. Laser ablation of the cervical pregnancy was performed achieving adequate homeostasis at the implantation site and preserving the intrauterine pregnancy. A healthy infant was delivered at 36 0/7 wks by cesarean-section.Laser ablation is a minimally invasive procedure that appears to lead to successful outcomes in treatment of heterotopic cervical pregnancy.
Source: Journal of Minimally Invasive Gynecology - Category: OBGYN Source Type: research
The objective of this study was 1) to assess the relationship between diagnosed DLP and cardiovascular disease in COPD patients and compare it with other known cardiovascular risk factors and 2) to determine the relationship between the different cardiovascular comorbidities and the severity groups according to the GOLD 2017 classification.MethodsA cross-sectional, observational study was performed in 454 outpatients with COPD during their follow up. We calculated the prevalence of each of the cardiovascular comorbidities and the probability of each of the cardiovascular risk factors to occur jointly with a vascular diseas...
Source: Revista Clinica Espanola - Category: Internal Medicine Source Type: research
The findings of recent clinical trials have shown that sodium-glucose co-transporter 2 (SGLT2) inhibitors produce effects beyond glucose lowering and have demonstrated beneficial cardiovascular effects that have been observed across a broad range of patients with type 2 diabetes mellitus. In particular, the cardiovascular benefit results largely from substantial and early effects of SGLT2 inhibition on cardiovascular death and hospitalization for heart failure. Recent cardiovascular outcomes trials (CVOTs) have also shown that relative risk reductions in cardiovascular outcomes were observed with SGLT2 inhibition both in p...
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Sodium-glucose co-transporter 2 (SGLT2) inhibitors immediately reduce the glomerular filtration rate (GFR) in patients with type 2 diabetes mellitus. When given chronically, they confer benefit by markedly slowing the rate at which chronic kidney disease progresses and are the first agents to do so since the advent of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). Salutary effects on the kidney were first demonstrated in cardiovascular outcomes trials and have now emerged from trials enriched in subjects with type 2 diabetes mellitus and chronic kidney disease.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Heart failure is a common complication among patients with type 2 diabetes mellitus and is associated with significantly increased risks of subsequent morbidity and mortality. Until recently, therapies and strategies were lacking to attenuate this excess risk of heart failure in this population. Sodium-glucose co-transporter 2 (SGLT2) inhibitors represent a unique class of glucose-lowering therapies that have multisystem health benefits. Three large cardiovascular outcomes trials have demonstrated consistent reductions in heart failure events among patients with type 2 diabetes mellitus with, or at risk for, atheroscleroti...
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Type 2 diabetes mellitus has long been recognized as a major risk factor for adverse atherosclerotic cardiovascular disease events; however, recent data indicate that heart failure is now emerging as the most common and morbid cardiovascular complication of type 2 diabetes mellitus. When heart failure develops in patients with type 2 diabetes, prognosis is ominous, highlighting the need for glucose-lowering therapies that can prevent heart failure, improve outcomes, or both. Prior to 2008, there was a paucity of randomized controlled trials evaluating long-term cardiovascular outcomes with glucose-lowering therapies.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Type 2 diabetes mellitus and congestive heart failure are highly prevalent diseases with significant morbidity and mortality. These 2 diseases often occur concurrently because of shared risk factors such as coronary artery disease, and also because type 2 diabetes mellitus has direct cardiotoxic effects. Type 2 diabetes mellitus likely has a causative role in the development and prognosis of patients with heart failure. Optimal prevention and treatment of type 2 diabetes mellitus and heart failure likely involves identifying and treating their shared pathophysiologic features.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Arguably, no class of medications, specifically for patients with type 2 diabetes mellitus, has garnered as much excitement as the sodium-glucose co-transporter 2 (SGLT2) inhibitors. Type 2 diabetes mellitus is a highly prevalent and growing global problem, and patients with type 2 diabetes mellitus are at high risk for cardiovascular and renal end-organ damage, complications, and mortality. Until recently, there was no proven therapy that reduced the risk of cardiovascular adverse events or death in these patients.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Source: Application of Clinical Genetics - Category: Genetics & Stem Cells Tags: The Application of Clinical Genetics Source Type: research
We report a case of a 36-year-old woman with type 2 diabetes mellitus and a one-year of primary infertility. Following oral ovulation induction cycles and IUI, diagnosis of heterotopic cervical pregnancy was made by ultrasonography at 7.4 weeks of gestation. Laser ablation of the cervical pregnancy was performed achieving adequate homeostasis at the implantation site and preserving the intrauterine pregnancy.
Source: The Journal of Minimally Invasive Gynecology - Category: OBGYN Authors: Tags: Case Repot Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Insulin | Laboratory Medicine | Middle East Health | Nutrition | Pathology | Study | Veterinary Research | Weight Loss